Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 16/20 | 0.55 |
| ▸ | RARB | P10826 | 7/20 | 0.55 |
| ▸ | RARA | P10276 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655879 | 0.88 | RARG (0.51) | RARGRARBRARAKDM4EALDH1A1 | |
| SCHEMBL955576 | 0.86 | RARG (0.57) | RARGRARBRARAKDM4EALDH1A1 | |
| SCHEMBL959752 | 0.86 | RARG (0.60) | RARGRARBRARAKDM4EALDH1A1 | |
| SCHEMBL956001 | 0.85 | RARG (0.76) | RARGRARBRARARXRA | |
| SCHEMBL955370 | 0.84 | RARG (0.75) | RARGRARBRARARXRA | |
| SCHEMBL958732 | 0.84 | RARG (0.58) | RARGRARBRARAKDM4EALDH1A1 | |
| SCHEMBL959850 | 0.84 | RARG (0.67) | RARGRARBRARAKDM4EALDH1A1 | |
| SCHEMBL956914 | 0.83 | RARG (0.65) | RARGRARBRARAKDM4EALDH1A1 | |
| SCHEMBL955464 | 0.83 | RARG (0.59) | RARGRARBRARAKDM4EALDH1A1 | |
| SCHEMBL4654839 | 0.83 | RARG (0.51) | RARGRARBRARAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872026-B2 | Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-01-18 | — | — | US | claimed |
| EP-1692093-B1 | BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2008-11-19 | — | — | EP | claimed |
| US-20070021473-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-01-25 | — | — | US | claimed |
| EP-1692093-A1 | BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2006-08-23 | — | — | EP | claimed |
| WO-2005056516-A1 | BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-23 | — | — | WO | claimed |
| US-7872026-B2 | Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-01-18 | — | — | US | disclosed |
| EP-1692093-B1 | BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2008-11-19 | — | — | EP | disclosed |
| US-20070021473-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-01-25 | — | — | US | disclosed |
| EP-1692093-A1 | BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005056516-A1 | BIPHENYL DERIVATIVES USEFUL AS LIGANDS THAT ACTIVATE THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021473-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | RARA, RARB, RARG | RARG 3/4885RARB 2/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.